The quest for targets executing MYC-dependent cell transformation

Frontiers in Oncology

Volumn 6, Issue JUN, 2016, Pages

  Hartl, Markus ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Carcinogenesis; Genetic; Oncogenes; Signal transduction; Transcription; Tumor suppressor

Indexed keywords

MYC PROTEIN;

CELL TRANSFORMATION; DNA TRANSCRIPTION; DOWN REGULATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR CLONING; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84982812922     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00132     Document Type: Short Survey

References (117)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
2. Vogt PK. Retroviral oncogenes: a historical primer. Nat Rev Cancer (2012) 12:639-48. doi:10.1038/nrc3320
3. Dang CV. MYC on the path to cancer. Cell (2012) 149:22-35. doi:10.1016/j.cell.2012.03.003
4. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 36:320-8. doi:10.1016/j.tibs.2011.03.006
5. Hartl M, Bister K. Oncogenes. 2nd ed. In: Maloy S, Hughes K, editors. Brenner's Encyclopedia of Genetics. (Vol. 5), San Diego: Academic Press (2013). p. 164-6.
6. Bister K, Hayman MJ, Vogt PK. Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology (1977) 82:431-48. doi:10.1016/0042-6822(77)90017-4
7. Jansen HW, Lurz R, Bister K, Bonner TI, Mark GE, Rapp UR. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature (1984) 307:281-4. doi:10.1038/307281a0
8. Bister K, Jansen HW. Oncogenes in retroviruses and cells: biochemistry and molecular genetics. Adv Cancer Res (1986) 47:99-188. doi:10.1016/S0065-230X(08)60199-2
9. Hartl M, Karagiannidis AI, Bister K. Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene (2006) 25:4043-55. doi:10.1038/sj.onc.1209441
10. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 6:635-45. doi:10.1038/nrm1703
11. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb Perspect Med (2014) 4:a014357. doi:10.1101/cshperspect.a014357
12. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev (2008) 22:2755-66. doi:10.1101/gad.1712408
13. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 79:7824-7. doi:10.1073/pnas.79.24.7824
14. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 14:455-67. doi:10.1038/nrc3760
15. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-MYC following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer (2006) 5:31. doi:10.1186/1476-4598-5-31
16. Coppola V, De Maria R, Bonci D. microRNAs and prostate cancer. Endocr Relat Cancer (2010) 17:F1-17. doi:10.1677/ERC-09-0172
17. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation cooperates with PTEN loss to drive c-MYC expression in advanced prostate cancer. Cancer Res (2012) 72:4765-76. doi:10.1158/0008-5472.CAN-12-0820
18. Castro IC, Breiling A, Luetkenhaus K, Ceteci F, Hausmann S, Kress S, et al. MYC-induced epigenetic activation of GATA4 in lung adenocarcinoma. Mol Cancer Res (2013) 11:161-72. doi:10.1158/1541-7786.MCR-12-0414-T
19. Hessmann E, Schneider G, Ellenrieder V, Siveke JT. MYC in pancreatic cancer: novel insights and their translation into therapeutic strategies. Oncogene (2016) 35:1609-18. doi:10.1038/onc.2015.216
20. Garbe JC, Vrba L, Sputova K, Fuchs L, Novak P, Brothman AR, et al. Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. Cell Cycle (2014) 13:3423-35. doi:10.4161/15384101.2014.954456
21. Vrba L, Garbe JC, Stampfer MR, Futscher BW. A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics (2015) 10:1074-83. doi:10.1080/15592294.2015.1106673
22. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene (1999) 18:3004-16. doi:10.1038/sj.onc.1202746
23. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature (2010) 463:899-905. doi:10.1038/nature08822
24. Hartl M, Mitterstiller AM, Valovka T, Breuker K, Hobmayer B, Bister K. Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra. Proc Natl Acad Sci U S A (2010) 107:4051-6. doi:10.1073/pnas.0911060107
25. Hartl M, Glasauer S, Valovka T, Breuker K, Hobmayer B, Bister K. Hydra myc2, a unique pre-bilaterian member of the myc gene family, is activated in cell proliferation and gametogenesis. Biol Open (2014) 3:397-407. doi:10.1242/bio.20147005
26. Young SL, Diolaiti D, Conacci-Sorrell M, Ruiz-Trillo I, Eisenman RN, King N. Premetazoan ancestry of the Myc-Max network. Mol Biol Evol (2011) 28:2961-71. doi:10.1093/molbev/msr132
27. Jackstadt R, Menssen A, Hermeking H. Genome-wide analysis of c-MYC-regulated mRNAs and miRNAs, and c-MYC DNA binding by next-generation sequencing. Methods Mol Biol (2013) 1012:145-85. doi:10.1007/978-1-62703-429-6_11
28. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell (1999) 3:169-79. doi:10.1016/S1097-2765(00)80308-1
29. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res (2012) 72:2622-33. doi:10.1158/0008-5472.CAN-11-3605
30. Herold S, Herkert B, Eilers M. Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer (2009) 9:441-4. doi:10.1038/nrc2640
31. Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 99:6274-9. doi:10.1073/pnas.082005599
32. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-MYC in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 100:8164-9. doi:10.1073/pnas.1332764100
33. Marinkovic D, Marinkovic T, Kokai E, Barth T, Möller P, Wirth T. Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res (2004) 32:5368-78. doi:10.1093/nar/gkh877
34. Kim J, Lee JH, Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One (2008) 3:e1798. doi:10.1371/journal.pone.0001798
35. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gütgemann I, Ehlers A, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One (2011) 6:e26837. doi:10.1371/journal.pone.0026837
36. Yap CS, Peterson AL, Castellani G, Sedivy JM, Neretti N. Kinetic profiling of the c-MYC transcriptome and bioinformatic analysis of repressed gene promoters. Cell Cycle (2011) 10:2184-96. doi:10.4161/cc.10.13.16249
37. Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene (2012) 31:1695-709. doi:10.1038/onc.2011.359
38. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov (2015) 5:1024-39. doi:10.1158/2159-8290.CD-15-0507
39. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 448:445-51. doi:10.1038/nature05953
40. Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One (2011) 6:e26057. doi:10.1371/journal.pone.0026057
41. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 151:56-67. doi:10.1016/j.cell.2012.08.026
42. Lovén J, Orlando DA, Sigova AA, Lin CY, Rahl PB, Burge CB, et al. Revisiting global gene expression analysis. Cell (2012) 151:476-82. doi:10.1016/j.cell.2012.10.012
43. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-MYC is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 151:68-79. doi:10.1016/j.cell.2012.08.033
44. Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature (2014) 511:488-92. doi:10.1038/nature13537
45. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature (2014) 511:483-7. doi:10.1038/nature13473
46. Wolf E, Lin CY, Eilers M, Levens DL. Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol (2015) 25:241-8. doi:10.1016/j.tcb.2014.10.006
47. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126:663-76. doi:10.1016/j.cell.2006.07.024
48. Andrechek ER. HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Oncogene (2015) 34:217-25. doi:10.1038/onc.2013.540
49. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A (2001) 98:4510-5. doi:10.1073/pnas.081074898
50. Hartl M, Nist A, Khan MI, Valovka T, Bister K. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc Natl Acad Sci U S A (2009) 106:5604-9. doi:10.1073/pnas.0812101106
51. Jackstadt R, Hermeking H. AP4 is required for mitogen-and c-MYC-induced cell cycle progression. Oncotarget (2014) 5:7316-27. doi:10.18632/oncotarget.2348
52. Fiaschetti G, Castelletti D, Zoller S, Schramm A, Schroeder C, Nagaishi M, et al. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene (2011) 30:2823-35. doi:10.1038/onc.2011.10
53. Yin XY, Grove L, Datta NS, Katula K, Long MW, Prochownik EV. Inverse regulation of cyclin B1 by c-MYC and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res (2001) 61:6487-93.
54. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 118:477-91. doi:10.1016/j.cell.2004.07.025
55. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature (1997) 387:422-6. doi:10.1038/387422a0
56. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 382:511-7. doi:10.1038/382511a0
57. Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol (2004) 24:7538-47. doi:10.1128/MCB.24.17.7538-7547.2004
58. Valovka T, Schönfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, et al. Transcriptional control of DNA replication licensing by Myc. Sci Rep (2013) 3:3444. doi:10.1038/srep03444
59. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, et al. HMG-I/Y, a new c-MYC target gene and potential oncogene. Mol Cell Biol (2000) 20:5490-502. doi:10.1128/MCB.20.15.5490-5502.2000
60. Teng SC, Chen YY, Su YN, Chou PC, Chiang YC, Tseng SF, et al. Direct activation of HSP90A transcription by c-MYC contributes to c-MYC-induced transformation. J Biol Chem (2004) 279:14649-55. doi:10.1074/jbc.M308842200
61. Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M, et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci U S A (2010) 107:3534-9. doi:10.1073/pnas.0901230107
62. Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huso DL, et al. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res (2005) 65:5620-7. doi:10.1158/0008-5472.CAN-05-0536
63. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-MYC target genes rcl and lactate dehydrogenase A. Cancer Res (2000) 60:6178-83.
64. Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis. Cell Rep (2016) 14:2337-47. doi:10.1016/j.celrep.2016.02.039
65. Tsuneoka M, Teye K, Arima N, Soejima M, Otera H, Ohashi K, et al. A novel Myc-target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma. J Biol Chem (2005) 280:19977-85. doi:10.1074/jbc.M501231200
66. Zhang XY, DeSalle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, et al. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 102:13968-73. doi:10.1073/pnas.0502330102
67. Rogulski KR, Cohen DE, Corcoran DL, Benos PV, Prochownik EV. Deregulation of common genes by c-MYC and its direct target, MT-MC1. Proc Natl Acad Sci U S A (2005) 102:18968-73. doi:10.1073/pnas.0507902102
68. Li Z, Boone D, Hann SR. Nucleophosmin interacts directly with c-MYC and controls c-MYC-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A (2008) 105:18794-9. doi:10.1073/pnas.0806879105
69. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell (2005) 7:433-44. doi:10.1016/j.ccr.2005.03.036
70. D'Artista L, Bisso A, Piontini A, Doni M, Verrecchia A, Kress TR, et al. Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc. Oncotarget (2016). doi:10.18632/oncotarget.7846
71. Orre RS, Cotter MA II, Subramanian C, Robertson ES. Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro. J Biol Chem (2001) 276:1794-9. doi:10.1074/jbc.M008560200
72. Wonsey DR, Zeller KI, Dang CV. The c-MYC target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci U S A (2002) 99:6649-54. doi:10.1073/pnas.102523299
73. Koh CM, Bezzi M, Low DH, Ang WX, Teo SX, Gay FP, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature (2015) 523:96-100. doi:10.1038/nature14351
74. O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-MYC enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 26:2373-86. doi:10.1128/MCB.26.6.2373-2386.2006
75. Ben-Porath I, Yanuka O, Benvenisty N. The tmp gene, encoding a membrane protein, is a c-MYC target with a tumorigenic activity. Mol Cell Biol (1999) 19:3529-39. doi:10.1128/MCB.19.5.3529
76. Reiter F, Hartl M, Karagiannidis AI, Bister K. WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. Oncogene (2007) 26:1769-79. doi:10.1038/sj.onc.1209975
77. Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, et al. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget (2015) 6:1157-70. doi:10.18632/oncotarget.2708
78. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-MYC oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res (2006) 66:5330-7. doi:10.1158/0008-5472.CAN-06-0037
79. Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science (1999) 283:676-9. doi:10.1126/science.283.5402.676
80. Li J, Kretzner L. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N-or c-myc. Mol Cell Biochem (2003) 250:91-105. doi:10.1023/A:1024918328162
81. Fog CK, Asmar F, Côme C, Jensen KT, Johansen JV, Kheir TB, et al. Loss of PRDM11 promotes MYC-driven lymphomagenesis. Blood (2015) 125:1272-81. doi:10.1182/blood-2014-03-560805
82. Rogulski K, Li Y, Rothermund K, Pu L, Watkins S, Yi F, et al. Onzin, a c-MYC-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene (2005) 24:7524-41. doi:10.1038/sj.onc.1208897
83. Watnick RS, Rodriguez RK, Wang S, Blois AL, Rangarajan A, Ince T, et al. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene (2015) 34:2823-35. doi:10.1038/onc.2014.228
84. Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A (2015) 112:5425-30. doi:10.1073/pnas.1501555112
85. Kim T, Cui R, Jeon YJ, Fadda P, Alder H, Croce CM. MYC-repressed long noncoding RNAs antagonize MYC-induced cell proliferation and cell cycle progression. Oncotarget (2015) 6:18780-9. doi:10.18632/oncotarget.3909
86. Kim T, Cui R, Jeon YJ, Lee JH, Lee JH, Sim H, et al. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci U S A (2014) 111:4173-8. doi:10.1073/pnas.1400350111
87. Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK. MYC regulates the non-coding transcriptome. Oncotarget (2014) 5:12543-54. doi:10.18632/oncotarget.3033
88. Frenzel A, Lovén J, Henriksson MA. Targeting MYC-regulated miRNAs to combat cancer. Genes Cancer (2010) 1:660-7. doi:10.1177/1947601910377488
89. Bui TV, Mendell JT. Myc: maestro of microRNAs. Genes Cancer (2010) 1:568-75. doi:10.1177/1947601910377491
90. Song R, Sponer N, He L. Methods to quantify microRNAs in the Myc gene network for posttranscriptional gene repression. Methods Mol Biol (2013) 1012:135-44. doi:10.1007/978-1-62703-429-6_10
91. Tao J, Zhao X, Tao J. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. Cell Cycle (2014) 13:191-8. doi:10.4161/cc.27646
92. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3:e2236. doi:10.1371/journal.pone.0002236
93. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 10:704-14. doi:10.1038/nrg2634
94. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 108:479-85. doi:10.1038/bjc.2012.581
95. Vermeersch KA, Wang L, McDonald JF, Styczynski MP. Distinct metabolic responses of an ovarian cancer stem cell line. BMC Syst Biol (2014) 8:134. doi:10.1186/s12918-014-0134-y
96. Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, et al. The butterfly effect in cancer: a single base mutation can remodel the cell. Proc Natl Acad Sci U S A (2015) 112:1131-6. doi:10.1073/pnas.1424012112
97. Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, et al. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF1. Cell Growth Differ (1999) 10:423-34.
98. Felts KA, Chen K, Zaharee K, Sundar L, Limjoco J, Miller A, et al. Functional cloning using pFB retroviral cDNA expression libraries. Mol Biotechnol (2002) 22:25-32. doi:10.1385/MB:22:1:025
99. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561-6. doi:10.1038/nature05945
100. Choi YL, Soda M, Ueno T, Hamada T, Haruta H, Yamoto A, et al. Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis (2012) 33:956-61. doi:10.1093/carcin/bgs099
101. Loftus SK, Larson DM, Watkins-Chow D, Church DM, Pavan WJ. Generation of RCAS vectors useful for functional genomic analyses. DNA Res (2001) 8:216-21. doi:10.1093/dnares/8.5.221
102. Gao SY, Jack MM, O'Neill C. Towards optimising the production of and expression from polycistronic vectors in embryonic stem cells. PLoS One (2012) 7:e48668. doi:10.1371/journal.pone.0048668
103. Charpentier E, Marraffini LA. Harnessing CRISPR-Cas9 immunity for genetic engineering. Curr Opin Microbiol (2014) 19C:114-9. doi:10.1016/j.mib.2014.07.001
104. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 346:6213. doi:10.1126/science.1258096
105. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 2:135-64. doi:10.18632/oncotarget.240
106. Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem (2016) 109:314-41. doi:10.1016/j.ejmech.2016.01.012
107. Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A (2015) 112:232-7. doi:10.1073/pnas.1422165112
108. Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin Q, et al. Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther (2015) 22:729-38. doi:10.1038/gt.2015.39
109. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun (2014) 5:4632. doi:10.1038/ncomms5632
110. Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, et al. Perturbation of the c-MYC-Max protein-protein interaction via synthetic α-helix mimetics. J Med Chem (2015) 58:3002-24. doi:10.1021/jm501440q
111. Marfil V, Blazquez M, Serrano F, Castell JV, Bort R. Growth-promoting and tumourigenic activity of c-MYC is suppressed by Hhex. Oncogene (2015) 34:3011-22. doi:10.1038/onc.2014.240
112. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A (2014) 111:12556-61. doi:10.1073/pnas.1319488111
113. Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, et al. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget (2014) 5:8869-78. doi:10.18632/oncotarget.2588
114. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 10:351-64. doi:10.1038/nrd3374
115. Lin CJ, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep (2012) 1:325-33. doi:10.1016/j.celrep.2012.02.010
116. Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer (2014) 14:32. doi:10.1186/1471-2407-14-32
117. Zhou Z, Patel M, Ng N, Hsieh MH, Orth AP, Walker JR, et al. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer (2014) 14:944. doi:10.1186/1471-2407-14-944